QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)

Pliant Therapeutics (PLRX) Stock Forecast, Price & News

$16.40
-0.16 (-0.97%)
(As of 09/28/2023 ET)
Compare
Today's Range
$16.01
$17.00
50-Day Range
$14.58
$20.15
52-Week Range
$14.47
$36.64
Volume
555,261 shs
Average Volume
805,271 shs
Market Capitalization
$981.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.55

Pliant Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
196.0% Upside
$48.55 Price Target
Short Interest
Bearish
10.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.65mentions of Pliant Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$2.60 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

263rd out of 969 stocks

Pharmaceutical Preparations Industry

104th out of 455 stocks


PLRX stock logo

About Pliant Therapeutics (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Price History

PLRX Stock News Headlines

Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
Why Shares of Pliant Therapeutics Are Rising Tuesday
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 4.7%
Stifel Nicolaus Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Company Calendar

Last Earnings
8/09/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.55
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+199.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-123,320,000.00
Net Margins
-2,872.79%
Pretax Margin
-2,872.79%

Debt

Sales & Book Value

Annual Sales
$9.69 million
Book Value
$6.43 per share

Miscellaneous

Free Float
56,483,000
Market Cap
$970.44 million
Optionable
Not Optionable
Beta
1.25
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 57)
    M.D., MBA, Ph.D., Pres, CEO & Director
    Comp: $1.06M
  • Dr. Keith Lamont Cummings M.B.A. (Age 46)
    M.D., Chief Financial Officer
    Comp: $662.34k
  • Mr. Mike Ouimette J.D. (Age 50)
    Gen. Counsel & Corp. Sec.
    Comp: $591.05k
  • Mr. Johannes P. Hull (Age 48)
    Chief Bus. Officer
    Comp: $631.64k
  • Dr. Éric Lefebvre M.D. (Age 59)
    Chief Medical Officer
    Comp: $763.49k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer













PLRX Stock - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price forecast for 2023?

11 brokerages have issued 1 year price targets for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they anticipate the company's share price to reach $48.55 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2023?

Pliant Therapeutics' stock was trading at $19.33 at the start of the year. Since then, PLRX shares have decreased by 16.1% and is now trading at $16.22.
View the best growth stocks for 2023 here
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.03. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $1.10 million. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative trailing twelve-month return on equity of 33.10%.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.45%), Deep Track Capital LP (6.77%), Casdin Capital LLC (2.84%), Polar Capital Holdings Plc (2.74%), Great Point Partners LLC (2.59%) and Franklin Resources Inc. (2.54%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends
.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $16.22.

How much money does Pliant Therapeutics make?

Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $970.44 million and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Pliant Therapeutics have?

The company employs 155 workers across the globe.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.

This page (NASDAQ:PLRX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -